Background The rationale behind this update of the 2016 British Society for Rheumatology
(BSR) guidelines on prescribing anti-rheumatic drugs in pregnancy and breastfeeding [1, 2] …

Background & Aims Biologics are used routinely in pregnant women with inflammatory
bowel disease (IBD), but large-scale data reporting adverse pregnancy outcomes among …

2. Methods This document represents the third version of the European Consensus on
reproduction in IBD. The development of this Consensus included the formulation of …

Background & Aims Pregnant women with inflammatory bowel disease (IBD) may require
biologic or thiopurine therapy to control disease activity. Lack of safety data has led to …

Im Jahr 2019 wurden etwa 25 500 Patient* innen mit M. Crohn im Krankenhaus stationär
behandelt [1]. Meistens tritt die Erkrankung in der Adoleszenz und im jungen …

Tumor necrosis factor-alpha (TNF-α) is a multifunctional Th1 cytokine and one of the most
important inflammatory cytokines. In pregnancy, TNF-α influences hormone synthesis …

Inflammatory bowel disease (IBD), as do most chronic inflammatory disorders, displays
unique features and confers different risk factors in male and female patients. Importantly …

Liver diseases in pregnancy comprise both gestational liver disorders and acute and chronic
hepatic disorders occurring coincidentally in pregnancy. Whether related to pregnancy or …

Background Women with inflammatory bowel diseases (IBD) often receive biologicals
during pregnancy to maintain disease remission. Data on outcome of vedolizumab‐exposed …

Since the late 1990s, tumor necrosis factor alpha (TNF-α) inhibitors (anti-TNFs) have
revolutionized the therapy of immune-mediated inflammatory diseases (IMIDs) affecting the …